Keryx Partners In Japan See Positive Results From Zerenex - Wall Street Journal PDF Print
Wall Street Journal
Keryx Biopharmaceuticals Inc. (KERX) said its Japanese partner has seen positive results from an advanced study of a treatment for hyperphosphatemia in end-stage kidney disease patients on dialysis. Shares of the drug company soared roughly 17% to ...
Keryx rises as Zerenex succeeds in Japan study BusinessWeek
JT/Torii report positive results from ferric citrate Phase 3 study for

...

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.